Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated content is consistent with the provided FDA labeling excerpts for DYANAVEL XR regarding abuse, misuse, and addiction risk, including diversion and overdose/death warning language, and includes appropriate citations to labeled sections.
Category Scores
Accurate Statements
Abuse, misuse, and addiction risk is supported by the FDA label for DYANAVEL XR.
Boxed Warning/5.1 states DYANAVEL XR has a high potential for abuse and misuse which can lead to substance use disorder including addiction.
The label addresses diversion for non-medical use into illicit channels/distribution.
Boxed Warning/5.1 and 9.2 both state DYANAVEL XR can be diverted for non-medical use.
Abuse/misuse can lead to overdose and death, with risk increased by higher doses and unapproved methods such as snorting or injection.
Boxed Warning/5.1 and 9.2 include overdose and death risk increased with higher doses or unapproved methods (snorting/injection).
Patient counseling includes educating patients/families about risks of abuse/misuse/addiction and that this can lead to overdose and death; advises safe storage and not sharing the drug.
Section 17 (Patient Counseling Information) includes education about abuse/misuse/addiction leading to overdose and death and instructions to store safely and not give to others.
Unsupported Statements
Contradictions
Important Omissions
No explicit labeling discussion provided for overdose clinical manifestations (e.g., cardiovascular/CNS effects) within the evaluated AI content, though those are in the provided excerpt from Overdosage (10).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated content accurately reflects labeled warnings about abuse/misuse/addiction and related overdose/death risk without adding incorrect or unsupported safety claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Minor omission: the AI content did not quote or summarize specific overdose clinical manifestations from Overdosage (10).
Suggested Improvement
Optionally include a brief reference to the label’s Overdosage (10) description of cardiovascular/CNS effects if the goal is a more comprehensive depiction of harms.